125 related articles for article (PubMed ID: 38643568)
1. Novel Pt(IV) complexes containing salvigenin ligand reverse cisplatin-induced resistance by inhibiting Rap1b-mediated cancer cell stemness in esophageal squamous cell carcinoma treatments.
Zhao J; Wu K; Yang Y; Liu D; Zhang C; Li X
Bioorg Chem; 2024 Jun; 147():107384. PubMed ID: 38643568
[TBL] [Abstract][Full Text] [Related]
2. Corilagin Inhibits Esophageal Squamous Cell Carcinoma by Inducing DNA Damage and Down-Regulation of RNF8.
Qiu F; Liu L; Lin Y; Yang Z; Qiu F
Anticancer Agents Med Chem; 2019; 19(8):1021-1028. PubMed ID: 30848215
[TBL] [Abstract][Full Text] [Related]
3. AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma.
Zhu Y; Yuan T; Zhang Y; Shi J; Bai L; Duan X; Tong R; Zhong L
Drug Des Devel Ther; 2019; 13():4321-4330. PubMed ID: 31908417
[TBL] [Abstract][Full Text] [Related]
4. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Design of Ferritin-Platinum Prodrugs for Targeted Therapy of Esophageal Squamous Cell Carcinoma.
Jiang B; Chen X; Wang S; Wang S; Ma S; Lu Y; Ma L; Liang Q; Xiao H; Zhang L; Yan X; Fan K
ACS Nano; 2024 Apr; 18(17):11217-11233. PubMed ID: 38627234
[TBL] [Abstract][Full Text] [Related]
6. Long non-coding RNA LINC00337 induces autophagy and chemoresistance to cisplatin in esophageal squamous cell carcinoma cells via upregulation of TPX2 by recruiting E2F4.
Yang C; Shen S; Zheng X; Ye K; Ge H; Sun Y; Lu Y
FASEB J; 2020 May; 34(5):6055-6069. PubMed ID: 32239565
[TBL] [Abstract][Full Text] [Related]
7. The PSMD14 inhibitor Thiolutin as a novel therapeutic approach for esophageal squamous cell carcinoma through facilitating SNAIL degradation.
Jing C; Li X; Zhou M; Zhang S; Lai Q; Liu D; Ye B; Li L; Wu Y; Li H; Yue K; Chen P; Yao X; Wu Y; Duan Y; Wang X
Theranostics; 2021; 11(12):5847-5862. PubMed ID: 33897885
[TBL] [Abstract][Full Text] [Related]
8. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
9. Construction of Dual Stimuli-Responsive Platinum(IV) Hybrids with NQO1 Targeting Ability and Overcoming Cisplatin Resistance.
Fang L; Qin X; Zhao J; Gou S
Inorg Chem; 2019 Feb; 58(3):2191-2200. PubMed ID: 30657321
[TBL] [Abstract][Full Text] [Related]
10. Glycyrrhetinic Acid as a Hepatocyte Targeting Ligand-Functionalized Platinum(IV) Complexes for Hepatocellular Carcinoma Therapy and Overcoming Multidrug Resistance.
Huang X; Li G; Li H; Zhong W; Jiang G; Cai J; Xiong Q; Wu C; Su K; Huang R; Xu S; Liu Z; Wang M; Wang H
J Med Chem; 2024 May; 67(10):8020-8042. PubMed ID: 38727048
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
[TBL] [Abstract][Full Text] [Related]
12. Toward overcoming cisplatin resistance via sterically hindered platinum(II) complexes.
Yu H; Gou S; Wang Z; Chen F; Fang L
Eur J Med Chem; 2016 May; 114():141-52. PubMed ID: 26974381
[TBL] [Abstract][Full Text] [Related]
13. Antitumour and antiangiogenic activities of [Pt(O,O'-acac)(γ-acac)(DMS)] in a xenograft model of human renal cell carcinoma.
Muscella A; Vetrugno C; Biagioni F; Calabriso N; Calierno MT; Fornai F; De Pascali SA; Marsigliante S; Fanizzi FP
Br J Pharmacol; 2016 Sep; 173(17):2633-44. PubMed ID: 27351124
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-153-3p regulates cell proliferation and cisplatin resistance via Nrf-2 in esophageal squamous cell carcinoma.
Zuo J; Zhao M; Fan Z; Liu B; Wang Y; Li Y; Lv P; Xing L; Zhang X; Shen H
Thorac Cancer; 2020 Mar; 11(3):738-747. PubMed ID: 32012470
[TBL] [Abstract][Full Text] [Related]
15. Platinum(IV) complexes conjugated with chalcone analogs as dual targeting anticancer agents: In vitro and in vivo studies.
Huang X; Liu Z; Wang M; Yin X; Wang Y; Dai L; Wang H
Bioorg Chem; 2020 Dec; 105():104430. PubMed ID: 33171407
[TBL] [Abstract][Full Text] [Related]
16. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
Wang Y; Wang X; Xu G; Gou S
J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
[TBL] [Abstract][Full Text] [Related]
17. Anti-cancer Effects of a Novel Quinoline Derivative 83b1 on Human Esophageal Squamous Cell Carcinoma through Down-Regulation of COX-2 mRNA and PGE
Pun IH; Chan D; Chan SH; Chung PY; Zhou YY; Law S; Lam AK; Chui CH; Chan AS; Lam KH; Tang JC
Cancer Res Treat; 2017 Jan; 49(1):219-229. PubMed ID: 27456944
[TBL] [Abstract][Full Text] [Related]
18. Lobaplatin promotes radiosensitivity, induces apoptosis, attenuates cancer stemness and inhibits proliferation through PI3K/AKT pathway in esophageal squamous cell carcinoma.
Pan S; Sun Y; Sui D; Yang T; Fu S; Wang J; Hui B; Xi R; He C; Zhang X
Biomed Pharmacother; 2018 Jun; 102():567-574. PubMed ID: 29597090
[TBL] [Abstract][Full Text] [Related]
19. Niacin-ligated platinum(iv)-ruthenium(ii) chimeric complexes synergistically suppress tumor metastasis and growth with potentially reduced toxicity in vivo.
Shu L; Ren L; Wang Y; Fang T; Ye Z; Han W; Chen C; Wang H
Chem Commun (Camb); 2020 Mar; 56(20):3069-3072. PubMed ID: 32049075
[TBL] [Abstract][Full Text] [Related]
20. HNRNPUL1 inhibits cisplatin sensitivity of esophageal squamous cell carcinoma through regulating the formation of circMAN1A2.
Li J; Sang M; Zheng Y; Meng L; Gu L; Li Z; Liu F; Wu Y; Li W; Shan B
Exp Cell Res; 2021 Dec; 409(1):112891. PubMed ID: 34688610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]